Cargando…

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses

BACKGROUND: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gristina, Valerio, Galvano, Antonio, Castellana, Luisa, Insalaco, Lavinia, Cusenza, Stefania, Graceffa, Giuseppa, Iacono, Federica, Barraco, Nadia, Castiglia, Marta, Perez, Alessandro, Rizzo, Sergio, Russo, Antonio, Bazan, Viviana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504650/ https://www.ncbi.nlm.nih.gov/pubmed/34646363 http://dx.doi.org/10.1177/17588359211018018

Ejemplares similares

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2019)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
por: Gkountakos, Anastasios, et al.
Publicado: (2021)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

Distribution and characterization of microplastics in marine sediments from the Montenegrin coast
por: Bošković, Neda, et al.
Publicado: (2022)

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

The impact of COVID-19 on tuberculosis: challenges and opportunities
por: Kant, Surya, et al.
Publicado: (2021)

Bronchial brushing Xpert improves the diagnostic efficiency of sputum Xpert in patients with pulmonary tuberculosis
por: He, Yu, et al.
Publicado: (2021)

The role of bronchoscopy in the diagnosis and management of pediatric pulmonary tuberculosis
por: Goussard, Pierre, et al.
Publicado: (2021)

Development of a nomogram for predicting treatment default under facility-based directly observed therapy short-course in a region with a high tuberculosis burden
por: Wang, Saibin
Publicado: (2021)

Addressing TB-related mortality in adults living with HIV: a review of the challenges and potential solutions
por: Sullivan, Amanda, et al.
Publicado: (2022)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
por: Listì, Angela, et al.
Publicado: (2019)

IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors
por: Nabbi, Arash, et al.
Publicado: (2022)

Epistemic modesty, ostentatiousness and the uncertainties of epigenetics: on the knowledge machinery of (social) science
por: Pickersgill, Martyn
Publicado: (2016)

Living well in the Neuropolis
por: Fitzgerald, Des, et al.
Publicado: (2016)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

Diabetic Retinopathy: Battling the Global Epidemic
por: Das, Arup
Publicado: (2016)

Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop
por: Nair, Prashant, et al.
Publicado: (2016)

Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases
por: Csaky, Karl, et al.
Publicado: (2018)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies
por: Levin, Leonard A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5cp8hul8tsakr9oav5d3dt3nph